{"entity":{"type":"insider","cik":"0001663607","url":"/insider/0001663607","json_url":"/insider/0001663607.json","name":"Harwin Peter Evan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":14,"first":"2023-07-17","last":"2026-07-20","span_basis":"filed_date"},"name_variants":[{"name":"Harwin Peter Evan","source":"filing","n_filings":14,"first_seen":"2023-07-17","last_seen":"2026-07-20"}],"transactions":[{"id":6226977,"accession":"0001104659-26-085113","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-085113","line_url":"/filing/0001104659-26-085113#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"CRESCENT BIOPHARMA, INC.","issuer_ticker":"CBIO","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas; Fairmount Funds Management LLC","owner_display_name":"Fairmount Healthcare Fund II L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":853450.0,"shares_display":"853,450","price_per_share":14.5,"price_display":"14.50","price_state":"stated","total_value":12375025.0,"total_display":"12,375,025.00","total_whole":"12,375,025","shares_owned_after":3601316.0,"shares_owned_after_display":"3,601,316","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-16","filed_date":"2026-07-20","scope":"insider"},{"id":5976645,"accession":"0001104659-26-080009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-080009","line_url":"/filing/0001104659-26-080009#line-2","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"Oruka Therapeutics, Inc.","issuer_ticker":"ORKA","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Fairmount Healthcare Co-Invest III L.P.; Harwin Peter Evan; Fairmount Funds Management LLC","owner_display_name":"Fairmount Healthcare Fund II L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3553410.0,"shares_display":"3,553,410","price_per_share":84.43,"price_display":"84.43","price_state":"stated","total_value":300014406.3,"total_display":"300,014,406.30","total_whole":"300,014,406","shares_owned_after":1131954.0,"shares_owned_after_display":"1,131,954","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-01","scope":"insider"},{"id":6109801,"accession":"0001104659-26-076967","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-076967","line_url":"/filing/0001104659-26-076967#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":null,"owner_name":"Kiselak Tomas; Harwin Peter Evan; Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.","owner_display_name":"Kiselak Tomas","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4684781.0,"shares_display":"4,684,781","price_per_share":85.31,"price_display":"85.31","price_state":"stated","total_value":399658667.11,"total_display":"399,658,667.11","total_whole":"399,658,667","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-23","filed_date":"2026-06-23","scope":"insider"},{"id":6226375,"accession":"0001104659-26-038546","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-038546","line_url":"/filing/0001104659-26-038546#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Kiselak Tomas","owner_display_name":"Fairmount Funds Management LLC","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":2359025.0,"shares_owned_after_display":"2,359,025","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-01","scope":"insider"},{"id":6084888,"accession":"0001104659-26-005921","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-005921","line_url":"/filing/0001104659-26-005921#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Kiselak Tomas","owner_display_name":"Fairmount Funds Management LLC","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750000.0,"shares_display":"1,750,000","price_per_share":76.3,"price_display":"76.30","price_state":"stated","total_value":133525000.0,"total_display":"133,525,000.00","total_whole":"133,525,000","shares_owned_after":298647.0,"shares_owned_after_display":"298,647","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-22","filed_date":"2026-01-22","scope":"insider"},{"id":4923420,"accession":"0001104659-25-119320","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-119320","line_url":"/filing/0001104659-25-119320#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"CRESCENT BIOPHARMA, INC.","issuer_ticker":"CBIO","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas; Fairmount Funds Management LLC","owner_display_name":"Fairmount Healthcare Fund II L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1360000.0,"shares_display":"1,360,000","price_per_share":13.41,"price_display":"13.41","price_state":"stated","total_value":18237600.0,"total_display":"18,237,600.00","total_whole":"18,237,600","shares_owned_after":2747866.0,"shares_owned_after_display":"2,747,866","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-04","filed_date":"2025-12-08","scope":"insider"},{"id":4112271,"accession":"0001104659-25-098362","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-098362","line_url":"/filing/0001104659-25-098362#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak Tomas","owner_display_name":"Fairmount Healthcare Fund II L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":316219.0,"shares_display":"316,219","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":6008161.0,"total_display":"6,008,161.00","total_whole":"6,008,161","shares_owned_after":2209025.0,"shares_owned_after_display":"2,209,025","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-07","filed_date":"2025-10-09","scope":"insider"},{"id":9223900,"accession":"0001104659-24-100766","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-100766","line_url":"/filing/0001104659-24-100766#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas","owner_display_name":"Fairmount Funds Management LLC","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":5100000.0,"total_display":"5,100,000.00","total_whole":"5,100,000","shares_owned_after":1892806.0,"shares_owned_after_display":"1,892,806","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-17","scope":"insider"},{"id":2837663,"accession":"0001104659-24-100330","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-24-100330","line_url":"/filing/0001104659-24-100330#line-5","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Harwin Peter Evan; Fairmount Funds Management LLC; Kiselak Tomas; Fairmount Healthcare Fund II L.P.","owner_display_name":"Harwin Peter Evan","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":5100000.0,"total_display":"5,100,000.00","total_whole":"5,100,000","shares_owned_after":1604891.0,"shares_owned_after_display":"1,604,891","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-16","scope":"insider"},{"id":8648772,"accession":"0001104659-23-106378","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-106378","line_url":"/filing/0001104659-23-106378#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Dianthus Therapeutics, Inc. /DE/","issuer_ticker":"DNTH","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Kiselak Tomas; Harwin Peter Evan; Fairmount Funds Management LLC","owner_display_name":"Kiselak Tomas","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24670.0,"shares_display":"24,670","price_per_share":13.63,"price_display":"13.63","price_state":"stated","total_value":336252.1,"total_display":"336,252.10","total_whole":"336,252","shares_owned_after":1928503.0,"shares_owned_after_display":"1,928,503","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-29","filed_date":"2023-10-03","scope":"insider"},{"id":8001324,"accession":"0001104659-23-104808","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-104808","line_url":"/filing/0001104659-23-104808#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Dianthus Therapeutics, Inc. /DE/","issuer_ticker":"DNTH","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Kiselak Tomas; Harwin Peter Evan","owner_display_name":"Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":13.15,"price_display":"13.15","price_state":"stated","total_value":394500.0,"total_display":"394,500.00","total_whole":"394,500","shares_owned_after":1903833.0,"shares_owned_after_display":"1,903,833","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-26","filed_date":"2023-09-28","scope":"insider"},{"id":7993534,"accession":"0000899243-23-019370","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-019370","line_url":"/filing/0000899243-23-019370#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Dianthus Therapeutics, Inc. /DE/","issuer_ticker":"DNTH","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Kiselak Tomas; Fairmount Funds Management LLC; Harwin Peter Evan","owner_display_name":"Kiselak Tomas","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":13.2,"price_display":"13.20","price_state":"stated","total_value":396000.0,"total_display":"396,000.00","total_whole":"396,000","shares_owned_after":1873833.0,"shares_owned_after_display":"1,873,833","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-21","scope":"insider"},{"id":7888702,"accession":"0000950170-23-048022","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-048022","line_url":"/filing/0000950170-23-048022#line-2","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Dianthus Therapeutics, Inc. /DE/","issuer_ticker":"DNTH","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak Tomas","owner_display_name":"Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9367.0,"shares_display":"9,367","price_per_share":11.76,"price_display":"11.76","price_state":"stated","total_value":110155.92,"total_display":"110,155.92","total_whole":"110,156","shares_owned_after":1843833.0,"shares_owned_after_display":"1,843,833","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-13","filed_date":"2023-09-13","scope":"insider"},{"id":7888700,"accession":"0000950170-23-048022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-048022","line_url":"/filing/0000950170-23-048022#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Dianthus Therapeutics, Inc. /DE/","issuer_ticker":"DNTH","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak Tomas","owner_display_name":"Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14887.0,"shares_display":"14,887","price_per_share":10.85,"price_display":"10.85","price_state":"stated","total_value":161523.95,"total_display":"161,523.95","total_whole":"161,524","shares_owned_after":1834466.0,"shares_owned_after_display":"1,834,466","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-12","filed_date":"2023-09-13","scope":"insider"},{"id":7844257,"accession":"0001104659-23-081729","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-23-081729","line_url":"/filing/0001104659-23-081729","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Healthcare Fund L.P.; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest II L.P.; Fairmount Funds Management LLC; Kiselak Tomas","owner_display_name":"Fairmount Healthcare Fund L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2941176.0,"shares_display":"2,941,176","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":49999992.0,"total_display":"49,999,992.00","total_whole":"49,999,992","shares_owned_after":1992734.0,"shares_owned_after_display":"1,992,734","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-13","filed_date":"2023-07-17","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001253689","name":"CRESCENT BIOPHARMA, INC.","url":"/issuer/0001253689","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2025-12-08","last_seen":"2026-07-20"},{"type":"issuer","type_label":"ISSUER","cik":"0000907654","name":"Oruka Therapeutics, Inc.","url":"/issuer/0000907654","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-07-01","last_seen":"2026-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001636282","name":"Spyre Therapeutics, Inc.","url":"/issuer/0001636282","role":"Director","n_filings":1,"first_seen":"2026-06-23","last_seen":"2026-06-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001953926","name":"Zenas BioPharma, Inc.","url":"/issuer/0001953926","role":"Director","n_filings":4,"first_seen":"2024-09-16","last_seen":"2026-04-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001974640","name":"Apogee Therapeutics, Inc.","url":"/issuer/0001974640","role":"Director","n_filings":2,"first_seen":"2023-07-17","last_seen":"2026-01-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001690585","name":"Dianthus Therapeutics, Inc. /DE/","url":"/issuer/0001690585","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2023-09-13","last_seen":"2023-10-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001663607","retrieved_at":"2026-08-22T13:39:46+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}